EGFR and non-small cell lung carcinoma: Outcomes from treatment with erlotinib and gefitinib in this New Zealand cohort of patients with advanced EGFR-mutant nonsquamous NSCLC were comparable to those reported in randomized controlled trials and other large-scale health care system–wide retrospective cohort studies.